Drug factory · FDA FEI 3008438216
PHARBIL Pharma GmbH
Reichenberger Str. 43, Bielefeld, Germany
Problems found, fixed voluntarily at FDA's last inspection, Jun 18, 2024.
Voluntary Action Indicated: inspectors found problems, but not serious enough for FDA to take action. The company is expected to fix them.
3 drug inspections on record since 2014: 2 with no problems, 1 with problems fixed voluntarily, 0 with FDA action.
What it does, for whom
| Drug | Role | For | NDC |
|---|---|---|---|
| Motixafortide | Tests it | BioLineRx USA Inc, Gamida Cell Inc. | 82737-073, 73441-062 |
FDA inspection history
| Ended | Result | Program | Problems noted |
|---|---|---|---|
| Jun 18, 2024 | Problems found, fixed voluntarily | Drug Quality Assurance | — |
| May 22, 2019 | No problems found | Drug Quality Assurance | — |
| Aug 29, 2014 | No problems found | Drug Quality Assurance | — |
Registered with FDA for: analysis.